Canagliflozin in Advanced Renal Disease With MRI Endpoints

Conditions: ESRD, CKD Stage 4, CKD Stage 5 Interventions: Drug: Canagliflozin 300Mg Tab; Drug: Placebo Sponsors: McGill University Health Centre/Research Institute of the McGill University Health Centre; Heart and Stroke Foundation of Canada Not yet recruiting

https://clinicaltrials.gov/study/NCT06182839

Source: ClinicalTrials.gov - December 27, 2023 Category: Research Source Type: clinical trials